Entropy Technologies LP Takes $1.34 Million Position in Repligen Corporation $RGEN

Entropy Technologies LP acquired a new position in Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,766 shares of the biotechnology company’s stock, valued at approximately $1,339,000.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after acquiring an additional 430,039 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after purchasing an additional 400,970 shares in the last quarter. Geneva Capital Management LLC lifted its position in Repligen by 239.6% during the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after purchasing an additional 343,991 shares during the last quarter. Nuveen LLC bought a new stake in Repligen during the first quarter valued at approximately $35,536,000. Finally, Primecap Management Co. CA grew its stake in Repligen by 348.1% in the 2nd quarter. Primecap Management Co. CA now owns 138,278 shares of the biotechnology company’s stock worth $17,199,000 after buying an additional 107,420 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 25,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the completion of the transaction, the director owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 49,382 shares of company stock valued at $7,676,802. 1.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research reports. Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Evercore ISI lifted their price target on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $173.85.

Repligen Trading Up 5.3%

NASDAQ:RGEN opened at $162.51 on Friday. The company has a 50-day moving average price of $144.66 and a 200-day moving average price of $130.31. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.15 billion, a price-to-earnings ratio of 8,129.56, a P/E/G ratio of 3.32 and a beta of 1.15.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The company had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter in the previous year, the company earned $0.43 earnings per share. Repligen’s quarterly revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.